SS Innovations Secures $18.6 Million in Private Placement to Advance Surgical Robotics Expansion

SS Innovations International, Inc. has completed a private placement of its common stock that generated approximately $18.6 million in gross proceeds. The financing, which closed on March 6, 2026, involved the sale of 5,774,839 shares of common stock. A portion of the offering, totaling approximately $5.2 million, was purchased by company leadership including Chairman and CEO Dr. Sudhir Srivastava, Vice-Chairman Dr. Frederic H. Moll, and director Tim Adams. The remaining shares, worth approximately $13.4 million, were sold to existing and new investors, led by existing shareholder Manipal Global Health Services.

The company intends to use the net proceeds from this financing for working capital and other general corporate purposes, specifically to advance its global expansion efforts. According to Dr. Srivastava, the funds will support growth initiatives in India and other existing global markets while preparing for entry into the United States and European Union markets. The company anticipates that the U.S. Food and Drug Administration will complete its review of the 510(k) premarket notification for the SSi Mantra surgical robotic system by mid-2026. SS Innovations also continues working toward European Union CE marking certification for the same system, which it believes can be obtained in 2026.

Dr. Srivastava emphasized that insider participation in the financing reflects strong confidence in the company's future and commitment to making robotic surgery accessible globally. He noted appreciation for the continuing support of Manipal Global Health Services and welcomed new shareholders to the company. The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption. This announcement does not constitute an offer to sell or solicitation of an offer to buy these securities.

In connection with a $2.5 million investment by one non-affiliate investor in the private placement, SS Innovations will pay a FINRA member firm a cash commission of $175,000 and issue five-year warrants to purchase 41,667 shares of common stock at an exercise price of $3.45 per share. The company develops surgical robotic technologies with a vision to make robotic surgery affordable and accessible globally. Its product range includes the SSi Mantra surgical robotic system and SSi Mudra surgical instruments, which support various procedures including cardiac surgery. The SSi Mantra system features modular robotic arms, an ergonomic surgeon command center, 3D 4K visualization, and utilizes over 40 different types of robotic endo-surgical instruments. The system has been clinically validated in India in more than 100 different types of surgical procedures. For more information, visit the company's website at https://ssinnovations.com.